Home Cart Sign in  
Chemical Structure| 923564-51-6 Chemical Structure| 923564-51-6

Structure of Navitoclax
CAS No.: 923564-51-6

Chemical Structure| 923564-51-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Navitoclax (ABT-263) is an orally active Bcl-2 inhibitor that binds to multiple Bcl-2 family proteins with Ki values of less than 1 nM.

Synonyms: ABT-263; A-855071

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Navitoclax

CAS No. :923564-51-6
Formula : C47H55ClF3N5O6S3
M.W : 974.61
SMILES Code : O=C(NS(=O)(C1=CC=C(N[C@H](CCN2CCOCC2)CSC3=CC=CC=C3)C(S(=O)(C(F)(F)F)=O)=C1)=O)C4=CC=C(N5CCN(CC6=C(C7=CC=C(Cl)C=C7)CCC(C)(C)C6)CC5)C=C4
Synonyms :
ABT-263; A-855071
MDL No. :MFCD12756219
InChI Key :JLYAXFNOILIKPP-KXQOOQHDSA-N
Pubchem ID :24978538

Safety of Navitoclax

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Bcl-xL

    Bcl-xL, Ki:<=0.5 nM

  • Bcl-w

    Bcl-w, Ki:<=1 nM

  • Bcl-2

    Bcl-2, Ki:<=1 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
H1975 cells 500 nM 48 h To assess the effect of RBM10 reconstitution on EGFR inhibitor-induced apoptosis, results showed that RBM10 reconstitution increased PARP cleavage and caspase 3/7 activity. PMC9246391
A014 cells 500 nM 48 h To assess the effect of RBM10 reconstitution on EGFR inhibitor-induced apoptosis, results showed that RBM10 reconstitution increased PARP cleavage and caspase 3/7 activity. PMC9246391
PC-9 cells 500 nM 48-72 h To assess the effect of RBM10 knockdown on EGFR inhibitor-induced apoptosis, results showed that RBM10 KD decreased PARP cleavage and caspase 3/7 activity. PMC9246391
H3255 cells 500 nM 48-72 h To assess the effect of RBM10 knockdown on EGFR inhibitor-induced apoptosis, results showed that RBM10 KD decreased PARP cleavage and caspase 3/7 activity. PMC9246391
MPM cells 1 µM 18-24 h To evaluate the apoptotic priming effect of Navitoclax in combination with AZD8055 on MPM cells, results showed that the combination significantly enhanced apoptosis. PMC10199949
De-iniDCs 1, 5, 10 μM overnight To evaluate the effect of Navitoclax on DC antigen presentation, results showed that Navitoclax enhanced the antigen presentation capability of DCs. PMC7615270
Liv7k oral cancer cell line 10 µM 72 h To test the growth inhibition effect of drugs under hypoxic and normoxic conditions, results showed that drugs with high cSL-scores exhibited stronger drug response in each condition separately. PMC6026173
MDA-MB-231 cells 10 µM 3 days To evaluate the effect of Navitoclax retreatment, it was found that cells remained sensitive to the drug upon retreatment. PMC8154902
MDA-MB-231 cells 10 µM 3 days To evaluate the cytotoxic effect of Navitoclax on MDA-MB-231 cells, it was found that cells were highly sensitive to 72 h treatment but fully recovered after 10 days in drug-free media. PMC8154902

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Sf3b1 K700E conditional knock-in mice Oral gavage 25 mg/kg 5 days per week for two weeks Test the combination effect of Navitoclax with Eltanexor, showing preferential sensitivity for SF3B1 mutant cells without excessive toxicity. PMC11347370
Mice H1975 subcutaneous xenografts Oral 50 mg/kg Daily for 14 days To evaluate the therapeutic effect of Navitoclax and Osimertinib combination therapy on RBM10-deficient EGFR-mutant tumors, results showed that the combination significantly increased tumor apoptosis. PMC9246391
Mice TNBC-PDX model Oral 100 mg/kg Once daily for 21 days To evaluate the tumor growth inhibitory effect of Navitoclax in combination with Metformin in TNBC-PDX model mice, results showed that the combination significantly inhibited tumor growth and extended survival. PMC6365524
Mice MPM PDX model Oral 100 mg/kg Once daily for 21 days To evaluate the efficacy of Navitoclax in combination with AZD8055 in the MPM PDX model, results showed that the combination significantly reduced tumor volume and increased mouse survival. PMC10199949
Mice Orthotopic MCA205 fibrosarcoma model Intraperitoneal injection 50 mg/kg Day 0 and day 2 To evaluate the activation of cDC1 cells by Navitoclax, results showed that Navitoclax significantly upregulated the activation markers of cDC1 cells. PMC7615270

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01423539 Diffuse Large B-Cell Lymphoma Phase 2 Withdrawn(The NAVIGATE study h... More >>as been terminated due to non-safety related reasons.) Less << February 2014 United States, California ... More >> Fountain Valley, California, United States, 92708 United States, Florida Hudson, Florida, United States, 34667 United States, Georgia Lawrenceville, Georgia, United States, 30045 United States, Illinois Centralia, Illinois, United States, 62801 Harvey, Illinois, United States, 60426 United States, Indiana Terre Haute, Indiana, United States, 47802 United States, Kentucky Hazard, Kentucky, United States, 41701 Paducah, Kentucky, United States, 42003 United States, Maryland Rockville, Maryland, United States, 20850 United States, Missouri Jefferson City, Missouri, United States, 65109 United States, Montana Great Falls, Montana, United States, 59405 United States, Ohio Newark, Ohio, United States, 43055 United States, Tennessee Nashville, Tennessee, United States, 37203 Less <<
NCT01053520 Healthy Female Subjects Phase 1 Completed - United States, Illinois ... More >> Site Reference ID/Investigator# 23602 Waukegan, Illinois, United States, 60085 Less <<
NCT01989585 BRAF V600E Mutation Present ... More >> BRAF V600K Mutation Present Metastatic Melanoma Solid Neoplasm Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Less << Phase 1 Phase 2 Recruiting - United States, California ... More >> University of California Davis Comprehensive Cancer Center Suspended Sacramento, California, United States, 95817 United States, Massachusetts Massachusetts General Hospital Cancer Center Withdrawn Boston, Massachusetts, United States, 02114 United States, Missouri Siteman Cancer Center at West County Hospital Suspended Creve Coeur, Missouri, United States, 63141 Washington University School of Medicine Suspended Saint Louis, Missouri, United States, 63110 Siteman Cancer Center-South County Suspended Saint Louis, Missouri, United States, 63129 Siteman Cancer Center at Christian Hospital Suspended Saint Louis, Missouri, United States, 63136 Siteman Cancer Center at Saint Peters Hospital Suspended Saint Peters, Missouri, United States, 63376 United States, New Jersey Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Site Public Contact    732-235-8675       Principal Investigator: Janice M. Mehnert          United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Site Public Contact    888-275-3853       Principal Investigator: James L. Abbruzzese          United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Site Public Contact    800-293-5066    Jamesline@osumc.edu    Principal Investigator: Kari L. Kendra          United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Site Public Contact    877-312-3961       Principal Investigator: Michael A. Davies Less <<
NCT02520778 EGFR Activating Mutation ... More >> EGFR Exon 19 Deletion Mutation EGFR NP_005219.2:p.G719X EGFR NP_005219.2:p.L858R EGFR NP_005219.2:p.L861Q EGFR NP_005219.2:p.T790M Stage III Non-Small Cell Lung Cancer AJCC v7 Stage IIIA Non-Small Cell Lung Cancer AJCC v7 Stage IIIB Lung Non-Small Cell Cancer AJCC v7 Stage IV Non-Small Cell Lung Cancer AJCC v7 Less << Phase 1 Recruiting - United States, California ... More >> University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Site Public Contact    916-734-3089       Principal Investigator: Jonathan W. Riess          United States, Colorado University of Colorado Hospital Active, not recruiting Aurora, Colorado, United States, 80045 United States, Florida Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612 Contact: Site Public Contact    800-456-7121    canceranswers@moffitt.org    Principal Investigator: Eric B. Haura          United States, Georgia Emory University Hospital/Winship Cancer Institute Recruiting Atlanta, Georgia, United States, 30322 Contact: Site Public Contact    404-778-1868       Principal Investigator: Suchita Pakkala          United States, Kentucky University of Kentucky/Markey Cancer Center Active, not recruiting Lexington, Kentucky, United States, 40536 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting Baltimore, Maryland, United States, 21287 Contact: Site Public Contact    410-955-8804    jhcccro@jhmi.edu    Principal Investigator: Christine L. Hann          United States, Massachusetts Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Site Public Contact    877-726-5130       Principal Investigator: Geoffrey R. Oxnard          Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact    877-442-3324       Principal Investigator: Geoffrey R. Oxnard          United States, New Jersey Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Site Public Contact    732-235-8675       Principal Investigator: Jyoti Malhotra          Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Site Public Contact    732-235-8675       Principal Investigator: Jyoti Malhotra          United States, North Carolina UNC Lineberger Comprehensive Cancer Center Recruiting Chapel Hill, North Carolina, United States, 27599 Contact: Site Public Contact    877-668-0683    cancerclinicaltrials@med.unc.edu    Principal Investigator: Jared M. Weiss          Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Site Public Contact    888-275-3853       Principal Investigator: James L. Abbruzzese          United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Site Public Contact    800-293-5066    Jamesline@osumc.edu    Principal Investigator: Erin M. Bertino          United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Site Public Contact    412-647-8073       Principal Investigator: Liza C. Villaruz          United States, Virginia University of Virginia Cancer Center Recruiting Charlottesville, Virginia, United States, 22908 Contact: Site Public Contact    434-243-6303    PAS9E@virginia.edu    Principal Investigator: Ryan D. Gentzler Less <<
NCT02079740 Advanced Malignant Solid Neopl... More >>asm KRAS Gene Mutation Metastatic Malignant Solid Neoplasm NRAS Gene Mutation Recurrent Colorectal Carcinoma Recurrent Lung Carcinoma Recurrent Malignant Solid Neoplasm Recurrent Pancreatic Carcinoma Stage III Colorectal Cancer AJCC v7 Stage III Lung Cancer AJCC v7 Stage III Pancreatic Cancer AJCC v6 and v7 Stage IIIA Colorectal Cancer AJCC v7 Stage IIIB Colorectal Cancer AJCC v7 Stage IIIC Colorectal Cancer AJCC v7 Stage IV Colorectal Cancer AJCC v7 Stage IV Lung Cancer AJCC v7 Stage IV Pancreatic Cancer AJCC v6 and v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 Unresectable Malignant Neoplasm Less << Phase 1 Phase 2 Recruiting - United States, Massachusetts ... More >> Massachusetts General Hospital Cancer Center Suspended Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Ryan B. Corcoran    877-726-5130       Principal Investigator: Ryan B. Corcoran Less <<
NCT03366103 Metastatic Malignant Solid Neo... More >>plasm Recurrent Malignant Solid Neoplasm Recurrent Small Cell Lung Carcinoma Stage III Small Cell Lung Carcinoma AJCC v7 Stage IIIA Small Cell Lung Carcinoma AJCC v7 Stage IIIB Small Cell Lung Carcinoma AJCC v7 Stage IV Small Cell Lung Carcinoma AJCC v7 Unresectable Solid Neoplasm Less << Phase 1 Phase 2 Recruiting May 31, 2020 United States, Maryland ... More >> Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting Baltimore, Maryland, United States, 21287 Contact: Site Public Contact    410-955-8804    jhcccro@jhmi.edu    Principal Investigator: Christine L. Hann          United States, Massachusetts Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Site Public Contact    877-726-5130       Principal Investigator: Anna F. Farago          Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Site Public Contact    888-823-5923    ctsucontact@westat.com    Principal Investigator: Anna F. Farago          Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact    617-667-9925       Principal Investigator: Anna F. Farago          Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact    877-442-3324       Principal Investigator: Anna F. Farago          United States, New Jersey Memorial Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Site Public Contact    212-639-7592       Principal Investigator: Wei-Chu V. Lai          Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Site Public Contact    212-639-7592       Principal Investigator: Wei-Chu V. Lai          United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Site Public Contact    212-639-7592       Principal Investigator: Wei-Chu V. Lai          Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Site Public Contact    212-639-7592       Principal Investigator: Wei-Chu V. Lai          Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Site Public Contact    212-639-7592       Principal Investigator: Wei-Chu V. Lai          Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States, 11570 Contact: Site Public Contact    212-639-7592       Principal Investigator: Wei-Chu V. Lai Less <<
NCT00445198 Small Cell Lung Cancer|Small C... More >>ell Lung Carcinoma Less << PHASE1|PHASE2 COMPLETED 2025-12-10 Site Reference ID/Investigator... More >># 13605, Peoria, Arizona, 85381, United States|Site Reference ID/Investigator# 5261, Phoenix, Arizona, 85013, United States|Site Reference ID/Investigator# 11942, Los Angeles, California, 90095-7187, United States|Site Reference ID/Investigator# 4718, Sacramento, California, 95817, United States|Site Reference ID/Investigator# 3755, Aurora, Colorado, 80045-0510, United States|Site Reference ID/Investigator# 8324, Atlanta, Georgia, 30322, United States|Site Reference ID/Investigator# 2623, Chicago, Illinois, 60612, United States|Site Reference ID/Investigator# 2625, Baltimore, Maryland, 21231-1000, United States|Site Reference ID/Investigator# 12343, Bethesda, Maryland, 20892, United States|Site Reference ID/Investigator# 11941, Boston, Massachusetts, 02215, United States|Site Reference ID/Investigator# 2626, Boston, Massachusetts, 02215, United States|Site Reference ID/Investigator# 4934, Charlotte, North Carolina, 28204, United States|Site Reference ID/Investigator# 2624, Nashville, Tennessee, 37203, United States|Site Reference ID/Investigator# 6650, Tacoma, Washington, 98405, United States|Site Reference ID/Investigator# 7493, Edmonton, T6G 1Z2, Canada|Site Reference ID/Investigator# 7635, Ottawa, K1H 8L6, Canada|Site Reference ID/Investigator# 18541, Leicester, LE1 5WW, United Kingdom|Site Reference ID/Investigator# 2622, Manchester, M20 4BX, United Kingdom Less <<
NCT00982566 Lymphoid Malignancy ... More >> Solid Tumors Less << Phase 1 Completed - -
NCT00481091 Chronic Lymphocytic Leukemia PHASE1|PHASE2 COMPLETED 2022-05-12 Moores Cancer Center at UC San... More >> Diego /ID# 5566, La Jolla, California, 92093, United States|Dana-Farber Cancer Institute /ID# 5547, Boston, Massachusetts, 02215, United States|University of Nebraska Medical Center /ID# 12261, Omaha, Nebraska, 68198, United States|North Shore University Hospital /ID# 12267, New Hyde Park, New York, 11040, United States|University of Texas MD Anderson Cancer Center /ID# 5575, Houston, Texas, 77030, United States|Northwest Medical Specialties - Tacoma /ID# 26428, Tacoma, Washington, 98405, United States|Peter MacCallum Cancer Ctr /ID# 6583, Melbourne, Victoria, 3000, Australia|The Royal Melbourne Hospital /ID# 5576, Parkville, Victoria, 3050, Australia|Universitaetsklinikum Koeln /ID# 5924, K?ln, Nordrhein-Westfalen, 50937, Germany|Leicester Royal Infirmary /ID# 15081, Leicester, England, LE1 5WW, United Kingdom Less <<
NCT02143401 Cirrhosis Hep... More >>atitis B Infection Hepatitis C Infection Metastatic Malignant Solid Neoplasm Recurrent Hepatocellular Carcinoma Recurrent Malignant Solid Neoplasm Refractory Malignant Neoplasm Stage IV Hepatocellular Carcinoma AJCC v7 Unresectable Solid Neoplasm Less << Phase 1 Recruiting - United States, Arizona ... More >> Mayo Clinic in Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Site Public Contact    855-776-0015       Principal Investigator: Brian A. Costello          United States, California University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Site Public Contact    916-734-3089       Principal Investigator: Edward J. Kim          United States, Colorado University of Colorado Hospital Recruiting Aurora, Colorado, United States, 80045 Contact: Site Public Contact    720-848-0650       Principal Investigator: Sarah L. Davis          United States, Florida Mayo Clinic in Florida Recruiting Jacksonville, Florida, United States, 32224-9980 Contact: Site Public Contact    855-776-0015       Principal Investigator: Brian A. Costello          United States, Iowa University of Iowa/Holden Comprehensive Cancer Center Recruiting Iowa City, Iowa, United States, 52242 Contact: Site Public Contact    800-237-1225       Principal Investigator: Mohammed M. Milhem          United States, Maryland University of Maryland/Greenebaum Cancer Center Recruiting Baltimore, Maryland, United States, 21201 Contact: Site Public Contact    800-888-8823       Principal Investigator: Edward A. Sausville          United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Site Public Contact    855-776-0015       Principal Investigator: Brian A. Costello          United States, New York Columbia University/Herbert Irving Cancer Center Recruiting New York, New York, United States, 10032 Contact: Site Public Contact    212-305-6361    nr2616@cumc.columbia.edu    Principal Investigator: Gulam A. Manji          United States, Pennsylvania Thomas Jefferson University Hospital Recruiting Philadelphia, Pennsylvania, United States, 19107 Contact: Site Public Contact    215-955-6084       Principal Investigator: James A. Posey          United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Site Public Contact    877-312-3961       Principal Investigator: Ahmed O. Kaseb Less <<
NCT03592576 - - - -
NCT01087151 Chronic Lymphocytic Leukemia Phase 2 Completed - -
NCT03181126 Acute Lymphoblastic Leukemia (... More >>ALL) Lymphoblastic Lymphoma Less << Phase 1 Recruiting June 17, 2020 United States, California ... More >> City of Hope /ID# 169029 Recruiting Duarte, California, United States, 91010 LPCH Stanford /ID# 163337 Recruiting Palo Alto, California, United States, 94304 United States, Illinois University of Chicago /ID# 163369 Recruiting Chicago, Illinois, United States, 60637 United States, Missouri Washington University-School of Medicine /ID# 165689 Recruiting Saint Louis, Missouri, United States, 63110 United States, North Carolina Univ NC Chapel Hill /ID# 163509 Recruiting Chapel Hill, North Carolina, United States, 27514-4220 United States, Ohio Cincinnati Children's Hospital /ID# 164619 Recruiting Cincinnati, Ohio, United States, 45229 Nationwide Childrens Hospital /ID# 163372 Recruiting Columbus, Ohio, United States, 43205 United States, Oregon Oregon Health and Science University /ID# 165690 Recruiting Portland, Oregon, United States, 97239-3098 United States, Tennessee St. Jude Childrens Res Hosp /ID# 163335 Recruiting Memphis, Tennessee, United States, 38105 United States, Texas UT Southwestern Medical Center /ID# 163346 Recruiting Dallas, Texas, United States, 75390-7208 MD Anderson Cancer Center /ID# 163327 Recruiting Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin-Madiso /ID# 165691 Recruiting Madison, Wisconsin, United States, 53705 Australia, Victoria Alfred Hospital /ID# 169576 Not yet recruiting Melbourne, Victoria, Australia, 3004 Victorian Comprehensive Cancer /ID# 165710 Recruiting Melbourne, Victoria, Australia, 3050 Royal Children's Hospital /ID# 163322 Recruiting Melbourne, Victoria, Australia, 3052 Less <<
NCT00406809 Chronic Lymphoid Leukemia|Lymp... More >>hoid Malignancies|Non-Hodgkin's Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Peripheral T-cell Lymphoma Less << PHASE1|PHASE2 COMPLETED 2025-10-16 Site Reference ID/Investigator... More >># 4997, Los Angeles, California, 90033, United States|Site Reference ID/Investigator# 9104, Los Angeles, California, 90095, United States|Site Reference ID/Investigator# 2613, Bethesda, Maryland, 20892, United States|Site Reference ID/Investigator# 40243, Boston, Massachusetts, 02215, United States|Site Reference ID/Investigator# 4745, Boston, Massachusetts, 02215, United States|Site Reference ID/Investigator# 2628, Buffalo, New York, 14263, United States|Site Reference ID/Investigator# 23543, New York, New York, 10016, United States|Site Reference ID/Investigator# 2627, New York, New York, 10021, United States|Site Reference ID/Investigator# 2614, New York, New York, 10032, United States|Site Reference ID/Investigator# 5383, New York, New York, 10065, United States|Site Reference ID/Investigator# 12306, Rochester, New York, 14642, United States|Site Reference ID/Investigator# 8941, Edmonton, T6G 1Z2, Canada Less <<
NCT01828476 Prostate Cancer Phase 2 Terminated(The Investigator le... More >>ft the organization.) Less << - United States, New Jersey ... More >> Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08901 Less <<
NCT00743028 Chronic Lymphocytic Leukemia ... More >> Lymphomas Leukemias Less << Phase 1 Completed - United States, California ... More >> Site Reference ID/Investigator# 10281 Encinitas, California, United States, 92024 Site Reference ID/Investigator# 10282 Santa Monica, California, United States, 90404 United States, Maryland Site Reference ID/Investigator# 16341 Bethesda, Maryland, United States, 20892 United States, New Hampshire Site Reference ID/Investigator# 9441 Lebanon, New Hampshire, United States, 03756 United States, New Jersey Site Reference ID/Investigator# 20041 Hackensack, New Jersey, United States, 07601 Less <<
NCT01828476 - Terminated(The Investigator le... More >>ft the organization.) Less << - -
NCT00888108 Solid Tumor Phase 1 Completed - United States, Arizona ... More >> Site Reference ID/Investigator# 51982 Scottsdale, Arizona, United States, 85258 United States, Florida Site Reference ID/Investigator# 44182 Fort Lauderdale, Florida, United States, 33308 United States, Maryland Site Reference ID/Investigator# 43962 Baltimore, Maryland, United States, 21231 Netherlands Site Reference ID/Investigator# 12844 Rotterdam, Netherlands, 3015 CE Site Reference ID/Investigator# 20042 Rotterdam, Netherlands, 3015 CE United Kingdom Site Reference ID/Investigator# 12845 Surrey, United Kingdom, SM2 5PT Less <<
NCT01557777 Chronic Lymphocytic Leukemia PHASE2 COMPLETED 2025-07-13 Site Reference ID/Investigator... More >># 74036, La Jolla, California, 92093-0698, United States|Site Reference ID/Investigator# 74035, Los Angeles, California, 90095-7059, United States|Site Reference ID/Investigator# 74038, Pleasant Hill, California, 94523, United States|Site Reference ID/Investigator# 74039, Santa Maria, California, 93454, United States|Site Reference ID/Investigator# 74033, Bethesda, Maryland, 20817, United States|Site Reference ID/Investigator# 79201, Coburg, 3058, Australia|Site Reference ID/Investigator# 78993, Greenslopes, 4120, Australia|Site Reference ID/Investigator# 77860, Afula, 18101, Israel|Site Reference ID/Investigator# 77637, Rechovot, 76100, Israel|Site Reference ID/Investigator# 77413, Gdansk, 80-952, Poland|Site Reference ID/Investigator# 79203, Ivano-Frankivsk, 76008, Ukraine|Site Reference ID/Investigator# 79205, Khmelnitsky, 29000, Ukraine|Site Reference ID/Investigator# 79202, Kyiv, 03115, Ukraine|Site Reference ID/Investigator# 79204, Lviv, 79044, Ukraine|Site Reference ID/Investigator# 79206, Poltava, 36024, Ukraine Less <<
NCT00868413 Chronic Lymphocytic Leukemia Phase 1 Completed - United States, California ... More >> Site Reference ID/Investigator# 17841 La Jolla, California, United States, 92093 Site Reference ID/Investigator# 25899 Stanford, California, United States, 94305-5821 United States, Maryland Site Reference ID/Investigator# 21622 Baltimore, Maryland, United States, 21231-1000 United States, Ohio Site Reference ID/Investigator# 21621 Columbus, Ohio, United States, 43210 United States, Pennsylvania Site Reference ID/Investigator# 39613 Philadelphia, Pennsylvania, United States, 19111 United States, Texas Site Reference ID/Investigator# 17943 Houston, Texas, United States, 77030-4009 Less <<
NCT01121133 Lymphoma, Including Chronic Ly... More >>mphocytic Leukemia Solid Tumors Less << Phase 1 Completed - -
NCT00918450 B-cell Chronic Lymphocytic Leu... More >>kemia Less << PHASE2 WITHDRAWN - -
NCT00788684 CD20-Positive Lymphoid Maligna... More >>ncies Chronic Lymphoid Leukemia Hematological Malignancies Non-Hodgkin's Lymphoma Less << Phase 1 Active, not recruiting April 30, 2020 United States, Arizona ... More >> University Arizona Cancer Ctr /ID# 16721 Tucson, Arizona, United States, 85719-1478 United States, California Stanford Univ School of Med /ID# 9782 Stanford, California, United States, 94305-2200 United States, Ohio Cleveland Clinic Foundation /ID# 9784 Cleveland, Ohio, United States, 44195 United States, Wisconsin Univ of Wisconsin Hosp/Clinics /ID# 21701 Madison, Wisconsin, United States, 53792-0001 Australia, Victoria Peter MacCallum Cancer Ctr /ID# 25067 Melbourne, Victoria, Australia, 3000 Royal Melbourne Hospital /ID# 9781 Parkville, Victoria, Australia, 3050 Less <<
NCT01009073 Solid Tumors Phase 1 Completed - United States, California ... More >> Site Reference ID/Investigator# 37463 Santa Monica, California, United States, 90404 United States, Michigan Site Reference ID/Investigator# 36342 Detroit, Michigan, United States, 48201 United States, Texas Site Reference ID/Investigator# 24046 San Antonio, Texas, United States, 78229 United States, Washington Site Reference ID/Investigator# 44917 Tacoma, Washington, United States, 98405 Less <<
NCT00891605 Solid Tumors Phase 1 Completed - -
NCT00887757 Solid Tumors Phase 1 Completed - -
NCT01021358 Lymphoma Chro... More >>nic Lymphocytic Leukemia Solid Tumors Less << Phase 1 Completed - United States, Texas ... More >> Site Reference ID/Investigator# 25068 San Antonio, Texas, United States, 78229 Less <<
NCT03222609 Myelofibrosis (MF) Phase 2 Recruiting June 11, 2021 United States, Alabama ... More >> UAB Comprehensive Cancer Cente /ID# 165464 Recruiting Birmingham, Alabama, United States, 35217 United States, California Ucsd /Id# 164084 Recruiting La Jolla, California, United States, 92037 Usc /Id# 164095 Recruiting Los Angeles, California, United States, 90033 United States, Florida Mayo Clinic /ID# 164201 Recruiting Jacksonville, Florida, United States, 32224 Moffitt Cancer Center /ID# 164082 Recruiting Tampa, Florida, United States, 33612 United States, Illinois University of Chicago /ID# 164115 Recruiting Chicago, Illinois, United States, 60637 United States, Indiana Indiana Blood & Marrow Transpl /ID# 165075 Recruiting Indianapolis, Indiana, United States, 46237 United States, Massachusetts Dana-Farber Cancer Institute /ID# 162675 Recruiting Boston, Massachusetts, United States, 02215 United States, Michigan Henry Ford Hospital /ID# 162682 Recruiting Detroit, Michigan, United States, 48202 United States, New York Weill Cornell Medical College /ID# 162679 Recruiting New York, New York, United States, 10021 United States, Texas MD Anderson Cancer Center /ID# 162683 Recruiting Houston, Texas, United States, 77030 UT Health Cancer Center /ID# 164094 Recruiting San Antonio, Texas, United States, 78229 United States, Utah University of Utah /ID# 164116 Recruiting Salt Lake City, Utah, United States, 84112-5500 United Kingdom Guy's and St Thomas' NHS Found /ID# 164110 Recruiting London, London, City Of, United Kingdom, SE1 9RT Christie NHS Foundation Trust /ID# 164111 Recruiting Manchester, United Kingdom, M20 4BX Less <<
NCT00878449 Solid Tumors Phase 1 Completed - United States, Illinois ... More >> Site Reference ID/Investigator# 13323 Chicago, Illinois, United States, 60637 Site Reference ID/Investigator# 12841 Maywood, Illinois, United States, 60153 United States, Maryland Site Reference ID/Investigator# 12303 Baltimore, Maryland, United States, 21231 United States, Massachusetts Site Reference ID/Investigator# 12305 Boston, Massachusetts, United States, 02215 Site Reference ID/Investigator# 20381 Boston, Massachusetts, United States, 02215 United States, Michigan Site Reference ID/Investigator# 43505 Detroit, Michigan, United States, 48202 United States, New Jersey Site Reference ID/Investigator# 13322 New Brunswick, New Jersey, United States, 08901 Less <<
NCT02591095 Platinum-resistant or Refracto... More >>ry Ovarian Cancer Less << PHASE2 COMPLETED 2025-03-19 CHU Besan?on - H?pital Jean Mi... More >>njoz, Besan?on, France|Institut Bergonié, Bordeaux, France|Centre Francois Baclesse, Caen, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|CHU, Lyon, France|ICM Val d'Aurelle, Montpellier, France|ICL Institut de Cancérologie de Lorraine, Nancy, France|Centre Catherine de Sienne, Nantes, France|ICO Centre René Gauducheau, Nantes, France|ICO Paul Papin, Nantes, France|Centre Antoine LACASSAGNE, Nice, France|H?pital Européen Georges Pompidou, Paris, France|H?pital Tenon, Paris, France|Institut Claudius Regaud, Toulouse, France|Gustave Roussy, Villejuif, France Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.03mL

0.21mL

0.10mL

5.13mL

1.03mL

0.51mL

10.26mL

2.05mL

1.03mL

References

 

Historical Records

Categories